IP Library Granted Patent US 9,931,311
Granted Patent B2
US 9,931,311 · App. 15/484,349 · Granted Apr 3, 2018

Treating critically ill patients with intravenous ibuprofen

Inventors: Leo Pavliv (Cary, NC); Amy Dix Rock (Nashville, TN)
Assignee: Cumberland Pharmaceuticals Inc.
A61K31/192A61K9/0019A61K9/08A61K31/197A61K45/06A61K47/183
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,931,311
App. No.
15/484,349
Granted
Apr 3, 2018
Kind
B2
Abstract

Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.

Claims (7)

1. A method of treating pain in critically ill patients in need thereof, comprising intravenously administering to critically ill patients an ibuprofen pharmaceutical composition comprising a dose of about 800 mg ibuprofen about every 4 to about 6 hours to treat pain in said patients to attain a mean Cmax from about 80% to about 125% of about 60 μg/ml, wherein the critically ill patients are not being treated for inflammation and are receiving at least one of the following: vasopressor support treatment, mechanical ventilation treatment, large volumes of blood products, have a pulmonary artery catheter treatment, an arterial blood pressure catheter treatment inserted, are being treated in an Intensive Care Unit, packed red blood cells administration, and multiple antibiotics administration; and pain is thereby treated.

2. The method of claim 1 , wherein the dose of intravenous ibuprofen administered provides a mean (AUC) within about 80% to about 125% of 94 μg.h/ml.

3. The method of claim 2 , wherein the critically ill patients are patients who are being treated in an Intensive Care Unit.

4. A method of treating pain in critically ill patients in need thereof, comprising intravenously administering to critically ill patients an ibuprofen pharmaceutical composition comprising a dose of about 400 mg ibuprofen about every 4 to about 6 hours to treat pain in said patients to attain a mean Cmax from about 80% to about 125% of about 25.7 μg/ml, wherein the critically ill patients are not being treated for inflammation and are receiving at least one of the following: vasopressor support treatment, mechanical ventilation treatment, large volumes of blood products, have a pulmonary artery catheter treatment, an arterial blood pressure catheter treatment inserted, are being treated in an Intensive Care Unit, packed red blood cells administration, and multiple antibiotics administration; and pain is thereby treated.

5. The method of claim 4 , wherein the dose of intravenous ibuprofen administered provides a mean (AUC) within about 80% to about 125% of 45.9 μg.h/ml.

6. The method of claim 4 , wherein the critically ill patients are patients who are being treated in an Intensive Care Unit.

7. The method of claim 5 , wherein the critically ill patients are patients who are being treated in an Intensive Care Unit.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2026
From: CUMBERLAND PHARMACEUTICALS INC.
To: APOTEX CORP.
Reel/Frame 075763/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2018
From: PAVLIV, LEO; ROCK, AMY DIX
To: CUMBERLAND PHARMACEUTICALS INC.
Reel/Frame 045415/0087 →
Continuity (8)
Continuation 14825803 · Aug 13, 2015
Continuation 14507331 · Oct 6, 2014
Continuation 12646499 · Dec 23, 2009
Continuation In Part 12570912 · Sep 30, 2009
Provisional Application 61230324 · Jul 31, 2009
Provisional Application 61230342 · Jul 31, 2009
Provisional Application 61225778 · Jul 15, 2009
Related Publication 20170216232A1 · Aug 3, 2017